Brca1 Knockout mouse models
Brca1 maintains genome integrity through homologous recombination repair. Pathogenic variants raise breast and ovarian cancer risk, so mouse models support BRCA directed therapy development and synthetic lethality screens. Tissue restricted knockouts help isolate mammary biology without early embryonic complications that can complicate whole body loss. Humanized alleles are useful when antibodies are human epitope selective. Well chosen floxed lines shorten the path from genetics to pharmacology cohorts.
Whole body loss of Brca1 gives the clearest readout when the question is whether the gene is required at all. Follow up tissue work may still move to a conditional allele if lethality or compensation appears.
Catalog table
A conventional knockout answers whether the gene is required broadly. When your target tissue is the organ of interest, a global null can still be informative if viability is acceptable and you want the simplest genotype. If the null is harsh, a floxed allele with a regional Cre is the safer long term platform.
A conventional knockout answers whether the gene is required broadly. When liver is the organ of interest, a global null can still be informative if viability is acceptable and you want the simplest genotype. If the null is harsh, a floxed allele with a regional Cre is the safer long term platform.
We do not list a Knockout allele for Brca1 in the live catalog yet. Use the quote path for a custom build.
Why this approach
A conventional knockout answers whether the gene is required broadly. When your target tissue is the organ of interest, a global null can still be informative if viability is acceptable and you want the simplest genotype. If the null is harsh, a floxed allele with a regional Cre is the safer long term platform.
A conventional knockout answers whether the gene is required broadly. When liver is the organ of interest, a global null can still be informative if viability is acceptable and you want the simplest genotype. If the null is harsh, a floxed allele with a regional Cre is the safer long term platform.
Build timeline and pricing
Typical custom projects target study ready cohorts near twenty six weeks from contract start when breeding is direct. Quotes return in about twenty four hours with milestones, pricing, and options for cryo or live dispatch.
Open the request quote formFAQ
How long does a Brca1 knockout project take?
Most custom knockout projects run near twenty six weeks from contract activation to study ready animals when breeding is straightforward. Complex humanization or multi allele stacks can add time. We return detailed quotes within about twenty four hours so you can align cohort start dates with grant or IND milestones.
Is Brca1 knockout embryonic lethal in mice?
Lethality depends on genetic background and exact allele design. Some Brca1 germline knockouts are viable, others require conditional alleles or mixed backgrounds. We review publications and our own experience, then recommend floxed versus null approaches before you commit.
Which Cre driver is best for experiments?
Driver choice depends on onset timing, recombination efficiency, and known leak patterns. We map your organ and cell type to a short list of proven Cre lines, then discuss reporter crosses and controls. We prioritize drivers with strong community validation for your tissue.
Do you ship live Brca1 animals?
When catalog lines are live, we ship with health certificates and QC documentation. If your exact combo is not listed, we quote a custom project with cryo or live dispatch options depending on cohort timing and geography.
How do I request a quote for Brca1?
Use the catalog inquire buttons or the request quote form with your allele goal, Cre plan if any, strain background, and cohort size. A PhD led team responds with pricing, milestones, and the fastest path to experimental animals.